[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.Read more
Through its Nanocyclix® technology, Oncodesign identifies small macrocyclic molecules capable of inhibiting with high potency and selectivity both known and unexplored kinases.
A wide variety of kinase inhibitors are continuously explored and the most promising inhibitor/kinase combinations are selected for further evaluation.
Oncodesign has built up a portfolio of projects with promising potential to treat serious diseases with no known treatment.
This portfolio contains both molecules already in advanced clinical development and molecules at an earlier stage of development.
Please contact Dr. Jan Hoflack – Chief Scientific Officer and Executive Director, Head of the Biotech BU – to discuss Oncodesign’s partnership and licensing opportunities:
– A pre-IND stage RIPK2 inhibitor with potential in multiple autoimmune and inflammatory indications is presented for partnership/licensing
– Programs in the optimization phase are available for partnership on attractive kinases: MNK1/2, ALK2, PIKFYVE, CDK7, PI3Kg, RET, FAK, ACK…
– Partnerships based on Nanocyclix® according to your kinase targets
We will be attending upcoming Biotech ShowCase in person to find value partners for licensing. The place to be to meet innovation’s actors.